10 results found.

Melanoma Clinical Trial using Dabrafenib

Memorial Sloan-Kettering Cancer Center - Recruiting 16 years or older.
- A Phase 2 Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation.
Dabrafenib

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of CTLA-4 Blockade for BRAF Mutant Melanoma.
dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

Malignant Melanoma Clinical Trial using Zelboraf (vemurafenib)

Genentech - Recruiting 16 years or older.
- An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E.
Zelboraf (vemurafenib)

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using cyclophosphamide; fludarabine phosphate; therapeutic tumor infiltrating lymphocytes; aldesleukin; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma.
cyclophosphamide; fludarabine phosphate; therapeutic tumor infiltrating lymphocytes; aldesleukin; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors.
dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, or Clinical Trial using ipilimumab; recombinant interferon alfa-2b; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma.
ipilimumab; recombinant interferon alfa-2b; quality-of-life assessment

Malignant Melanoma Clinical Trial using vemurafenib

Hoffmann-La Roche - Recruiting 12 years to 17 years.
- An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of RO5185426 in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Mutations.
vemurafenib

Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, or Clinical Trial using recombinant hsp110-gp100 chaperone complex vaccine

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma.
recombinant hsp110-gp100 chaperone complex vaccine

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using ipilimumab; recombinant interferon alfa-2b; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma.
ipilimumab; recombinant interferon alfa-2b; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma.
riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study